

Amendments to the Claims:

1-27. (canceled)

28. (currently amended) An isolated native sequence polypeptide having at least 80% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:374;
 - (b) the amino acid sequence of the polypeptide of SEQ ID NO:374, lacking its associated signal peptide; or
 - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203465;
- wherein the nucleic acid encoding the polypeptide is amplified in lung or colon tumors.

29. (currently amended) The isolated native sequence polypeptide of Claim 28 having at least 85% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:374;
 - (b) the amino acid sequence of the polypeptide of SEQ ID NO:374, lacking its associated signal peptide; or
 - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203465;
- wherein the nucleic acid encoding the polypeptide is amplified in lung or colon tumors.

30. (currently amended) The isolated native sequence polypeptide of Claim 28 having at least 90% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:374;
 - (b) the amino acid sequence of the polypeptide of SEQ ID NO:374, lacking its associated signal peptide; or
 - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203465;
- wherein the nucleic acid encoding the polypeptide is amplified in lung or colon tumors.

31. (currently amended) The isolated native sequence polypeptide of Claim 28 having at least 95% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:374;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:374, lacking its associated signal peptide; or
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203465;

wherein the nucleic acid encoding the polypeptide is amplified in lung or colon tumors.

32. (currently amended) The isolated native sequence polypeptide of Claim 28 having at least 99% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:374;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:374, lacking its associated signal peptide; or
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203465;

wherein the nucleic acid encoding the polypeptide is amplified in lung or colon tumors.

33. (previously presented) An isolated polypeptide comprising:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:374;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:374, lacking its associated signal peptide; or
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203465.

34. (previously presented) The isolated polypeptide of Claim 33 comprising the amino acid sequence of the polypeptide of SEQ ID NO:374.

35. (previously presented) The isolated polypeptide of Claim 33 comprising the amino acid sequence of the polypeptide of SEQ ID NO:374, lacking its associated signal peptide.

36. (canceled)

37. (canceled)

38. (previously presented) The isolated polypeptide of Claim 33 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203465.

39. (previously presented) A chimeric polypeptide comprising a polypeptide according to Claim 28 fused to a heterologous polypeptide.

40. (previously presented) The chimeric polypeptide of Claim 39, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.